Church & Dwight
CHD
$94.58
+1.81%
Church & Dwight Co., Inc. is a leading consumer packaged goods company operating in the Household & Personal Products industry, best known as the global producer of Arm & Hammer baking soda. The company has evolved into a diversified portfolio manager of value-driven brands, with its core portfolio—including Arm & Hammer, OxiClean, Batiste, and Vitafusion—accounting for approximately 70% of its sales and profits. The current investor narrative centers on the company's ability to navigate a competitive and inflationary environment for consumer staples, with recent attention focused on its strategic acquisitions, such as Touchland, and its ongoing efforts to drive growth through brand investment and market share gains in its core categories while maintaining its defensive characteristics.…
CHD
Church & Dwight
$94.58
CHD 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Church & Dwight's 12-month outlook, with a consensus price target around $122.95 and implied upside of +30.0% versus the current price.
Average Target
$122.95
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$76 - $123
Analyst target range
The stock is covered by 7 analysts, indicating solid institutional interest. The consensus sentiment appears neutral to cautiously optimistic, as reflected in recent institutional ratings which include actions like 'Hold', 'Neutral', 'In Line', and 'Equal-Weight', alongside a few 'Buy' or 'Overweight' ratings; the average estimated EPS for the period is $4.71, with a revenue estimate of approximately $7.14 billion. The target price range implied by the EPS estimates is wide, with a low of $4.65 and a high of $4.96, representing a spread of about 6.7% around the average; this moderate spread indicates a reasonable level of consensus on near-term earnings, though the range of revenue estimates from $7.07B to $7.44B points to some uncertainty around top-line growth drivers and macroeconomic impacts on the consumer.
Bulls vs Bears: CHD Investment Factors
The evidence presents a balanced but nuanced picture, with a slight edge to the bullish case based on strong fundamentals and a defensive recovery narrative. The bull thesis is anchored in CHD's robust cash generation, high profitability, low volatility, and steady operational execution. The bear case focuses on its premium valuation, modest growth profile, and significant historical underperformance. The single most important tension in the investment debate is whether the market will continue to reward CHD's defensive qualities and cash-generative stability with a premium multiple, or if its modest growth trajectory will lead to valuation compression towards sector averages. The resolution of this tension hinges on the company's ability to demonstrate accelerated organic growth or more consistent margin expansion.
Bullish
- Strong Free Cash Flow Generation: The company generated $1.093 billion in TTM free cash flow, providing significant financial flexibility. This robust cash generation supports a $300 million Q4 share repurchase, a dividend with a 39% payout ratio, and strategic acquisitions like Touchland without straining the balance sheet.
- Solid Profitability and ROE: CHD maintains a strong trailing net margin of 11.88% and an impressive Return on Equity of 18.41%. This high ROE, coupled with a moderate debt-to-equity ratio of 0.55, demonstrates efficient use of capital and a durable competitive moat around its core brands.
- Defensive Profile with Low Beta: The stock's beta of 0.473 indicates it is roughly 53% less volatile than the broader market, a classic defensive characteristic. This low systematic risk profile makes CHD a potential haven during market downturns, as evidenced by its 13.09% YTD outperformance versus the SPY's 4.14% gain.
- Steady Sequential Revenue Growth: Quarterly revenue grew sequentially from $1.467B in Q1 to $1.644B in Q4 2025, demonstrating consistent low-single-digit growth. The Q4 revenue also showed a 3.93% year-over-year increase, indicating resilience and market share gains in a competitive consumer staples environment.
Bearish
- Elevated Valuation Multiples: CHD trades at a forward P/E of 24.2x and a trailing P/E of 27.62x, which is at a premium to the broader consumer staples sector. The PEG ratio of approximately 1.02 suggests the stock is fairly valued for its growth, leaving little room for multiple expansion unless earnings accelerate.
- Modest Top-Line Growth Trajectory: While sequential growth is positive, the year-over-year revenue growth of 3.93% is modest. Analyst revenue estimates for the coming period range from $7.07B to $7.44B, indicating uncertainty and a lack of consensus on a significant growth acceleration.
- Margin Volatility and Pressure: Gross margin fluctuated between 42.95% and 45.85% across the 2025 quarters, reflecting ongoing input cost pressures and product mix challenges. This volatility highlights the company's exposure to inflationary pressures in a competitive pricing environment.
- Poor Relative Strength vs. Market: Despite recent recovery, CHD's 1-year relative strength against the SPY is -42.96%. This severe underperformance indicates the market has heavily discounted defensive stocks during the recent bull market, and a sustained sector rotation may be needed for CHD to close this gap.
CHD Technical Analysis
The stock is in a pronounced recovery phase within a longer-term downtrend, trading 8.06% lower over the past year but having rallied 17.23% year-to-date as of the current date. With a current price of $96.88, the stock is positioned at approximately 58% of its 52-week range ($81.33 to $106.04), indicating it has recovered meaningfully from its lows but remains well below its recent peak, suggesting room for further recovery if the positive momentum holds. Recent short-term momentum is notably strong and diverges from the weak annual performance, with the stock up 6.92% over the past three months and 1.19% over the past month, signaling a potential trend reversal or a significant relief rally from oversold conditions. The stock exhibits low systematic risk with a beta of 0.473, meaning it is roughly 53% less volatile than the broader market, which is characteristic of its defensive sector but also implies muted participation in strong market rallies, as evidenced by its 1-year relative strength of -42.96% against the SPY. Key technical levels are clearly defined by the 52-week high of $106.04, which now serves as major resistance, and the 52-week low of $81.33, which established a firm support base during the October 2025 sell-off; a decisive breakout above $106 would signal a full recovery and a resumption of the long-term uptrend, while a breakdown below $81.33 would invalidate the recent recovery and likely lead to a test of deeper support levels.
Beta
0.47
0.47x market volatility
Max Drawdown
-26.3%
Largest decline past year
52-Week Range
$81-$106
Price range past year
Annual Return
-7.4%
Cumulative gain past year
| Period | CHD Return | S&P 500 |
|---|---|---|
| 1m | +0.8% | +8.5% |
| 3m | +2.3% | +2.8% |
| 6m | +10.1% | +4.6% |
| 1y | -7.4% | +32.3% |
| ytd | +14.4% | +3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CHD Fundamental Analysis
Revenue growth has been modest but positive, with Q4 2025 revenue of $1.644 billion representing a 3.93% year-over-year increase; however, examining the sequential quarterly trend from Q1 to Q4 2025 reveals revenue figures of $1.467B, $1.506B, $1.586B, and $1.644B, indicating a pattern of steady, low-single-digit sequential growth throughout the fiscal year. The company is solidly profitable, with Q4 2025 net income of $143.5 million and a trailing twelve-month net margin of 11.88%; gross margin for the quarter was healthy at 45.85%, though it has shown some quarterly fluctuation between 42.95% and 45.85% in 2025, reflecting the impact of input cost pressures and product mix. The balance sheet and cash flow position are robust, characterized by a moderate debt-to-equity ratio of 0.55, a strong return on equity of 18.41%, and substantial free cash flow generation of $1.093 billion on a TTM basis, which provides ample liquidity for dividends, share repurchases ($300 million in Q4), and strategic acquisitions without straining the financial structure.
Quarterly Revenue
$1.6B
2025-12
Revenue YoY Growth
+0.03%
YoY Comparison
Gross Margin
+0.45%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CHD Overvalued?
Given the company's consistent profitability, the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 27.62x and a forward PE of 24.20x based on estimated EPS; the forward multiple being lower than the trailing multiple suggests analysts expect earnings growth, with the implied forward earnings growth rate aligning with the PEG ratio of approximately 1.02. Compared to sector averages, the valuation appears elevated; while direct industry average multiples are not provided in the data, the forward PE of 24.2x is typically at a premium to the broader consumer staples sector, which may be justified by Church & Dwight's strong brand portfolio, above-average ROE of 18.41%, and consistent free cash flow generation. Historically, the current trailing PE of 27.62x sits above the multi-year range observable in the historical ratios data, which has fluctuated significantly from negative values during loss-making quarters to highs in the mid-30s; trading near the upper end of its own historical band suggests the market is pricing in a stable recovery and normalized earnings, leaving limited room for multiple expansion unless growth accelerates meaningfully.
PE
27.6x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -85x~40x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: CHD's primary financial risk is not leverage, given its moderate 0.55 debt-to-equity ratio, but rather its ability to sustain premium valuation multiples in the face of modest growth. The stock's forward P/E of 24.2x demands consistent execution; any earnings miss could trigger a sharp de-rating. Furthermore, gross margin volatility (42.95%-45.85% in 2025) exposes the company to persistent input cost inflation, which could pressure the healthy 11.88% net margin if not fully passed through to consumers. Revenue concentration, with ~80% of sales in the US, also presents a geographic concentration risk limiting diversification benefits.
Market & Competitive Risks: The most significant market risk is valuation compression. Trading at a forward P/E premium to its sector, CHD is vulnerable to a rotation out of defensive stocks if economic optimism persists, as seen in its -42.96% 1-year relative strength. Its low beta of 0.473, while defensive, also implies muted upside participation in strong bull markets. Competitively, the household products space is intensely crowded, with large rivals possessing greater scale, potentially limiting CHD's pricing power and market share gains for its core brands like Arm & Hammer and OxiClean.
Worst-Case Scenario: The worst-case scenario involves a combination of an earnings miss, a sector-wide de-rating of defensive stocks, and a resurgence of cost inflation. This could break the recent technical recovery, leading the stock to re-test and potentially break below its 52-week low of $81.33. Given the stock's historical max drawdown of -26.33% and the current price of $96.88, a realistic adverse scenario could see a decline of approximately 16% to the prior low. A more severe bear case, incorporating multiple compression, could push the stock towards the $75-$80 range, representing a downside of 17-22% from current levels.